PHARMAXIS COMPLETES ENROLLMENT IN ARIDOL COPD TRIAL
Pharmaxis has completed enrollment in its clinical trial to test Aridol's ability to predict response to treatment in patients with chronic obstructive pulmonary disease.
The trial began in September 2005 and is being conducted at 11 hospitals in five states across Australia. Patients who volunteer for the trial receive an Aridol test followed by 12 weeks of treatment with an inhaled steroid to control lung inflammation. The trial will record differences in lung function, quality of life and the general health of the patient.